Stoke Therapeutics, Inc(NASDAQ:STOK) 
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentat...
Website: http://www.stoketherapeutics.com
Founded: 2015
IPO Price: $18 (Jun 19, 2019)
Full Time Employees: 56
CEO: Edward M. Kaye
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 6.07
H 6.20
L 5.66
C 5.94
V 1,135,454
10EMA 5.94
20EMA 5.94
60EMA 5.94
120EMA 5.94
250EMA 5.94